Uroxal

Quick links to important sections

Uroxal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uroxal

Uroxal is a synthetic drug defined as a specialized medication used to modulate the involuntary activity of the bladder muscle. The medicine's core purpose, clinically recognized for its efficacy, is to restore better control over urination patterns by calming the excessive signaling that causes frequent and sudden urges.


Quick Facts about Uroxal

Property Description
Active ingredient Oxybutynin chloride
Forms Tablet (IR and ER), Syrup, Transdermal patch
Pharmacological class Anticholinergic / Urinary antispasmodic
General purpose Increasing bladder capacity
Origin Synthetic drug (tertiary amine)

What Type of Medicine is Uroxal?

Uroxal is primarily classified as an anticholinergic agent, functionally known as a urinary antispasmodic. The active ingredient responsible for its function is Oxybutynin chloride, a tertiary amine compound that acts on specific receptors within the urinary tract. The drug exerts a direct spasmolytic effect on bladder smooth muscle, which relaxes the muscle and eases tension. Its differentiation lies in its established history as a first-line antispasmodic agent, utilizing a mechanism involving muscarinic receptor antagonism to block premature contraction signals.


Composition and Available Forms of Uroxal

The composition of Uroxal is centered on the single active ingredient, Oxybutynin chloride, combined with pharmaceutical excipients necessary for its various delivery methods. The drug is available for both oral and transdermal administration, offering differentiation through several distinct dosage forms such as a tablet, a syrup, and a transdermal patch (transdermal system). The extended-release (ER) tablet, specifically, represents a key innovation designed for the sustained-release of the active compound over a longer duration, which provides consistent therapeutic levels and may reduce dosing frequency compared to traditional immediate-release (IR) forms.


Uroxal: General Purpose and Therapeutic Role

The general therapeutic purpose of Uroxal is to relieve symptoms related to the bladder’s muscular overactivity by allowing the organ to hold a greater volume of urine. This physiological action—reducing detrusor muscle contractility—serves to diminish the severity of disruptive symptoms such as high urinary frequency, strong urgency, and involuntary urine leakage. By modulating these core issues, the drug supports the patient’s ability to manage their daily routine with improved control over the timing and necessity of urination.

What side effects are possible with Uroxal?

Possible Side Effects and Safety Information

The safety profile of Uroxal (oxybutynin chloride) is based on official classifications defined by regulatory authorities, which group adverse reactions by frequency and the affected body system. The occurrence of these reactions is directly related to the medicine's pharmacological properties, concentrating in the nervous, gastrointestinal, and ocular system organ classes.

Frequency Classification of Adverse Reactions

The most frequently documented effects (Very Common) reflect the drug's primary activity.

Frequency Tier Example Adverse Reactions (SOC)
Very Common (ge 1/10) Dry mouth, constipation, headache, dizziness, somnolence, blurred vision
Common (ge 1/100 to < 1/10) Nausea, diarrhea, dyspepsia, insomnia, dry eyes, urinary retention
Uncommon (ge 1/1,000 to < 1/100) Vomiting, anorexia, dysphagia

Reactions with a Frequency Not Known (cannot be estimated from available data) include angioedema, cognitive disorders, convulsions, hallucinations, tachycardia, and arrhythmia. These classifications establish the high prevalence of expected effects like dry mouth and constipation.

Serious Safety Considerations

Official labeling cites several serious adverse reactions. These include potentially life-threatening events such as angioedema (swelling beneath the skin), severe cognitive impairment, and the risk of heat stroke due to decreased sweating (hypohidrosis). Central Nervous System (CNS) reactions, like hallucinations and agitation, are specifically noted to be more likely to occur or worsen in the first few months after beginning treatment or increasing the dose.

Population-Specific Safety Notes

Regulatory documents recognize specific safety considerations for patient populations. The risk of CNS effects, including cognitive impairment, is documented as generally greater in older adults. Furthermore, caution is advised for individuals with significantly impaired hepatic (liver) or renal (kidney) function due to the potential for increased systemic exposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Uroxal (oxybutynin chloride) is officially documented as an exaggeration of the known anticholinergic effects, which constitutes a serious medical emergency. This profile is defined by acute disturbances in the Central Nervous System (CNS) and the Cardiovascular System.


Documented Overdose Manifestations

The clinical signs of overdose may include severe CNS effects such as restlessness, excitement, psychotic behavior, hallucinations, tremor, and potentially convulsions or coma. Cardiovascular manifestations include flushing, a pronounced drop in blood pressure (hypotension), and tachycardia (rapid heart rate), potentially leading to circulatory disturbance. Other reported signs are fever, hot and dry skin, and respiratory failure.


Required Emergency Action

Regulatory guidance uniformly requires that in the event of a suspected or confirmed overdose, immediate medical attention must be sought. Patients or caregivers must contact a poison control center or seek emergency medical care immediately. Management is classified as symptomatic and supportive. Official labeling notes that no specific antidote is known, though management procedures may involve gastric lavage, administration of cathartics, or the use of physostigmine for severe CNS symptoms. Hospital monitoring is required for continued observation and management of unstable symptoms.

Therapeutic Uses of Uroxal

Uroxal is commonly used to help manage symptoms related to heightened physiological activity in the bladder, particularly in conditions where functional stability becomes affected. It is applied across therapeutic domains where additional symptomatic support is needed to help manage distressing urges.


What Uroxal Treats: Main Uses and Benefits

Uroxal is primarily relevant for managing the core symptom clusters of Overactive Bladder (OAB), a condition characterized by periods of heightened symptoms that may interfere with daily functioning. This includes easing the intensity of urinary urgency, frequency, and is relevant for managing urge incontinence (involuntary leakage). The medication is also applied in specialized clinical settings involving neurological conditions (such as spina bifida) that result in bladder muscle instability.

The medication is used to help manage the sudden urges to urinate that may be hard to control. The key therapeutic benefit provided by Uroxal supports the storage capacity of the bladder, which may assist the organ in holding urine for longer periods. This action may assist with managing nocturia—the need to wake up and urinate multiple times at night—and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Support for Urgency and Frequency

Symptom Domain Primary Benefit
OAB & Urgency Helps address the intensity of sudden, compelling urges.
Nocturia May assist with managing nocturia.
Incontinence Relevant for easing symptomatic discomfort from involuntary leakage.

This supportive therapy assists with maintaining functional stability for these specific patient groups.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Uroxal?

Uroxal (Oxybutynin chloride) eligibility is strictly defined by regulatory documents, distinguishing between approved populations, restricted use, and absolute contraindications.

Contraindicated Populations (Must Not Use)

Uroxal is contraindicated for patients with specific health conditions due to regulatory restrictions:

  • Urinary Retention or Gastric Retention.
  • Uncontrolled Narrow-Angle Glaucoma.
  • Known Hypersensitivity to the active ingredient or excipients.
  • Severe Decreased Gastrointestinal Motility (e.g., paralytic ileus, toxic megacolon).
  • Myasthenia Gravis (in some jurisdictions).

Age and Physiological Restrictions

Population Group Eligibility Status
Adults (18+) Approved for use in unstable bladder conditions.
Pediatric (Under 5/6) Not recommended; safety and efficacy are not established.
Frail Elderly Use with caution due to increased risk of side effects.
Renal/Hepatic Impairment Use with caution; dosage adjustment or increased monitoring may be required.
Pregnancy/Lactation Not recommended; safety is not established for use during these periods.

Eligibility is conditional upon the absence of absolute contraindications and is limited by age minimums and the presence of organ impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Uroxal's interaction profile is officially documented based on effects related to drug metabolism and additive pharmacological actions.

Drug–Drug Interactions

Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin, Clarithromycin) is documented to increase the systemic exposure of Oxybutynin and its active metabolite. This pharmacokinetic interaction occurs due to the reduced clearance of Uroxal.

Concomitant use with other anticholinergic drugs or CNS depressants (including certain antihistamines, tricyclic antidepressants, and sedatives) may result in additive pharmacodynamic effects, officially enhancing side effects such as drowsiness, confusion, and dry mouth. This additive risk extends to frail elderly patients and those with dementia receiving cholinesterase inhibitors, where the potential for central nervous system effects is increased.

Specific Restrictions

Regulatory labeling establishes a specific restriction on co-administering Uroxal with solid oral dosage forms of potassium salts (Potassium Chloride, Potassium Citrate). This is classified as a restriction because Uroxal's effect of decreasing gastrointestinal motility increases the risk of local irritation and potential gastrointestinal lesions from the potassium salts.

Uroxal's effect on gastrointestinal movement may also antagonize the action of prokinetic agents, which are used to increase motility.

Interactions with Substances

Co-administration with alcohol is documented to enhance the sedative effects of Uroxal. Official statements on the extended-release tablet note that its pharmacokinetics are not significantly altered by food.

Mechanism of Action

How Uroxal Works


Primary Mechanism: Cholinergic Signal Blockade

Uroxal acts primarily as a competitive antagonist against muscarinic acetylcholine receptors, particularly the M3 subtype, which mediates contraction in the detrusor smooth muscle. By blocking the binding site for acetylcholine, the drug interrupts the excitatory signal from the parasympathetic nervous system, suppressing the cascade leading to uncontrolled detrusor depolarization.


Complementary Spasmolytic Action

Beyond receptor antagonism, the drug exerts a secondary, non-selective spasmolytic effect by inhibiting the flow of calcium ions into the detrusor muscle cells. Since calcium is essential for muscle contraction, this mechanism complements the receptor blockade, contributing directly to reduced muscle tone and functionally maintaining detrusor muscle relaxation.


Physiological Result: Increased Storage Capacity

The engagement of these dual mechanisms leads to a core physiological outcome: the detrusor muscle exhibits reduced excitability and tone. This directly decreases intravesical pressure during filling, increasing the volume the bladder can physically accommodate. This modulation governs the physical parameters of urinary storage.

Dosage and Administration Information

How Uroxal Is Used

The usage of Uroxal (Oxybutynin chloride) is determined by its specific formulation, defining the official route of administration and the required dosing schedule. The medicine is authorized for use as Oral tablets (immediate-release or IR, and extended-release or ER) and syrup, or as a Topical/Transdermal patch.


Official Dosing Schedules

Dosage Form Adult Starting Dose Maximum Daily Dose Frequency
IR Oral (Tablet/Syrup) 5 mg two to three times daily 20 mg Multiple times daily
ER Oral (Tablet) 5 mg or 10 mg once daily 30 mg Once daily
Transdermal Patch 3.9 mg/day (one patch) 3.9 mg/day Twice weekly

Administration and Procedural Rules

Specific rules govern the intake of Uroxal to ensure correct use as established for its use. The Extended-Release (ER) tablet must be swallowed whole with liquids and must not be chewed, divided, or crushed. This form may be administered with or without food and should be taken at the same time each day.

For the Transdermal Patch, the system is applied to intact skin, and the application site must be rotated. Users are instructed not to re-apply the patch to the same skin site within a 7-day period. Dosage adjustment for the ER tablet is systematic, occurring in 5-mg increments at approximately weekly intervals.

Age-Specific Use

Administration rules specify lower starting doses for older adults. Pediatric dosing is also defined by form: the IR tablet is approved for children 5 years (maximum 15 mg/day), and the ER tablet is approved for children 6 years (maximum 20 mg/day).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uroxal

The main evidence from research exploring Uroxal in the context of Overactive Bladder (OAB) symptoms—such as sudden, strong urges and frequent urination—comes from numerous short-term Randomized Controlled Trials (RCTs). These studies were used to explore patterns observed in symptoms over time when participants were assigned Uroxal compared to a placebo (an inactive treatment).

Outcomes Examined in OAB Clinical Trials

Research monitored several key outcomes reflecting daily functioning or activity level. Studies measured the frequency of daily urination episodes and tracked the number of times involuntary leakage (urge incontinence) occurred in the observed populations. Researchers also examined the measured increase in functional bladder capacity. Research describes patterns that were monitored in the studies over defined time intervals, typically lasting 6 to 12 weeks. The evidence contributes to understanding short-term symptom patterns in this patient group.


Evidence for Specialized Neurological Bladder Conditions

Uroxal was also studied for a distinct set of conditions involving the bladder, specifically neurogenic detrusor overactivity, which is bladder instability resulting from specific neurologic conditions. The research relies on Randomized Controlled Trials (RCTs) of varying sizes, supported by observational studies. This area of research primarily focused on outcomes monitoring physiological measures of bladder function using urodynamic testing.

Key Limitations and Areas for Future Research

Clinical trials for Uroxal primarily focused on short-term symptom changes. As a result, long-term effects are not fully established through extensive controlled data. High participant dropout rates were observed in some studies, which can impact the data used to understand sustained patterns of use. The overall evidence quality is noted to vary across studies, especially those examining neurogenic bladder, where subgroup findings are uncertain due to modest sample sizes.

Key Studies & References

  1. Oxybutynin: MedlinePlus Drug Information (used for standard indications, populations, and general evidence scope)
  2. Oxybutynin - LiverTox - NCBI Bookshelf - NIH (used for general evidence profile and safety data regarding rare events)
  3. [Clinical effects of oxybutynin hydrochloride in the treatment of unstable bladder and overactive neurogenic bladder: a long-term clinical trial] (used for long-term and NDO observational/follow-up data)
  4. EMA Assessment Report - Oxybutynin (used for regulatory context and general benefit-risk balance assessment)

Frequently Asked Questions (FAQ)

Common questions about Uroxal (FAQ)


Q: Is Uroxal a generic or a brand-name medication?

The active ingredient in Uroxal is oxybutynin chloride, which is the drug's generic name. The name Uroxal itself is the brand name used by the manufacturer to market the medication. Other brand names containing this same active ingredient are also available.

Q: Is there a generic version available for Uroxal?

Yes, regulatory information indicates that generic versions of the medicine are widely available. Approved generic forms containing oxybutynin chloride, in both immediate-release and extended-release tablets, are marketed for patient use.

Q: How long does it typically take before Uroxal starts working?

Official pharmacological data indicates that the immediate-release (IR) tablet is rapidly absorbed after oral intake. Peak concentration in the bloodstream is generally reached within about one hour. This rate of absorption relates to the time when the drug becomes available to the body's systems.

Q: Does Uroxal cause weight gain or weight loss?

Official listings of adverse reactions note that unusual weight gain or loss has been reported by some users. However, these reports are generally categorized as reactions with a frequency that is not known or considered rare, meaning they are not common effects.

Q: Can men and women take Uroxal for the same conditions?

Yes, official product information confirms that the medicine is approved for use in both adult men and women. Its indications are for the relief of symptoms related to bladder overactivity, such as overactive bladder (OAB) or neurogenic detrusor overactivity, regardless of gender.

Q: Can I take Uroxal if I have a history of heart problems?

Official labeling indicates that caution is required in patients who have certain existing heart conditions. These conditions include coronary heart disease, congestive heart failure, or specific cardiac arrhythmias and tachycardia, as the medicine may aggravate these symptoms.

Q: What should I do if I forget to take a dose of Uroxal?

Official product labeling describes the instruction for a missed dose as follows: if a dose is missed, taking it as soon as remembered is typically advised. However, if it is almost time for the next dose, the guidance is to skip the missed dose entirely to avoid taking a double dose.

Q: Is Uroxal addictive or habit-forming?

No, the active ingredient, oxybutynin chloride, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). This means official agencies do not consider it to have the potential for abuse or dependence.

Q: Can Uroxal be taken with over-the-counter pain relievers like ibuprofen or acetaminophen?

Concomitant use with over-the-counter Nonsteroidal Anti-inflammatory Medications (NSAIDs), such as ibuprofen, may increase the potential risk of certain side effects. However, official information suggests it is generally safe to take with acetaminophen (paracetamol).

Q: Does Uroxal interact with herbal supplements like St. John's Wort or ginkgo?

The medicine is metabolized in the body primarily through the CYP3A4 enzyme system. Official warnings indicate that any herbal supplements that affect this enzyme system, such as St. John's Wort (an enzyme inducer), could alter the amount of Uroxal in your body.

Q: Is Uroxal used for conditions other than its main approved use (off-label clarification)?

Official regulatory documents state that the medicine is indicated only for the relief of symptoms of bladder instability. These approved conditions include overactive bladder (OAB) and neurogenic detrusor overactivity.

Q: Will I need regular blood tests while I am taking Uroxal?

Official safety information notes that caution is required in patients who have impaired hepatic (liver) or renal (kidney) function. In these specific cases, a healthcare professional may require increased monitoring, which could potentially include blood tests.

Q: Does Uroxal interact with oral contraceptives or birth control pills?

Regulatory and clinical reviews suggest that there is generally no known interaction that reduces the effectiveness of oral contraceptives when co-administered with this medication. However, if the medication causes severe vomiting or diarrhea, this may reduce the efficacy of your oral contraceptive.

Q: Do I need a prescription to get Uroxal?

Yes, the oral tablet, syrup, and extended-release tablet forms of this medicine are officially designated as Prescription Only (Rx Only) drugs by regulatory bodies. It cannot be purchased over-the-counter.

Q: Is Uroxal considered a controlled substance?

The medicine is not scheduled by the U.S. Drug Enforcement Administration (DEA). This official classification means that it is not classified as a controlled substance and is not considered to have a potential for abuse or dependence.

Q: What should I do if my Uroxal prescription expires?

Official storage and disposal instructions advise against keeping medicine that is outdated or no longer needed. Official disposal guidelines state that a pharmacist or healthcare professional can be consulted for instruction on the proper disposal of any unused or outdated medicine, in accordance with local pharmaceutical waste guidelines.

Q: Are there any special considerations for teenagers taking Uroxal?

Official dosing information approves the medicine for pediatric use starting at ages five or six, depending on the form. Teenagers generally fall within the approved dosing ranges established for older children or adults. Any specific considerations regarding a patient's treatment regimen are determined by a prescribing physician.

How should Uroxal be stored and disposed of?

How to Store and Dispose of Uroxal (Oxybutynin Chloride)

Uroxal tablets must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its tightly closed original container and requires protection from moisture and excessive heat; it is mandatory that the product is not frozen.

Storage Restriction Requirement
Temperature Controlled room temperature (Do not freeze)
Container Keep tightly closed in original container
Safety Keep out of the sight and reach of children

For disposal, unused or expired Uroxal should not be thrown into household waste or wastewater. Consult a pharmacist or healthcare professional for instruction on discarding the medicine in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uroxal found in:

A-Z Index: